First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis

Abstract Background Anti-drug antibodies (ADAs) can impact on the efficacy and safety of biologicals, today used to treat several chronic inflammatory conditions. Specific patient groups may be more prone to develop ADAs. Rituximab is routinely used for ANCA-associated vasculitis (AAV) and as off-la...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Francesca Faustini, Nicky Dunn, Nastya Kharlamova, Malin Ryner, Annette Bruchfeld, Vivianne Malmström, Anna Fogdell-Hahn, Iva Gunnarsson
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	BMC 2021-08-01
Reeks:	Arthritis Research & Therapy
Onderwerpen:	Rituximab Anti-drug antibodies (ADA) Systemic lupus erythematosus ANCA-associated vasculitis Disease activity B cell counts
Online toegang:	https://doi.org/10.1186/s13075-021-02589-6
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!